DUSP4 and breast cancer: The idea that MKP-2 plays a role in chemotherapy response is also supported by a recent study by Balko et al [24], in which molecular profiling of basal-like breast cancer tissues revealed that loss of MKP-2 expression was associated with increased ERK pathway activation and reduced disease-free survival following neo-adjuvant chemotherapy.